Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
Favipiravir is an anti-viral medication, which is a pyrazine carboxamide derivative. Chemically, 6-fluoro-3hydroxy-2-pyrazine carboxamide is an anti-viral agent which selectively and potentially inhibits the activity of RNA dependent RNA polymerase enzyme in the virus. This prevents the viral replication process and hence, the virus is unable to replicate inside the host. The drug is sold under the trade name of Avigan and was originally developed by the Japanese company Fujifilm Toyoma Chemicals Co. Ltd., for the treatment of influenza.
Asia Pacific favipiravir market is expected to grow at an impressive rate during the forecast period. The Asia Pacific favipiravir market is driven by the extensive use of this drug in the treatment of COVID-19 disease as it has similar mechanism of action against the COVID-19 virus it has against the influenza virus. The drug inhibits the activity of RNA polymerase and COVID-19 is unable to replicate. At present, there is no drug available for the treatment of novel coronavirus and it has been identified that favipiravir is helpful in its treatment. The drug is being extensively used in China and Japan in the Asia Pacific region for the treatment of COVID-19. A study was conducted in China on 80 people to study the effect of the drug. There was also a control group which was administered lopinavir/ritonavir, the HIV inhibiting drugs which are also being recognized as a potential treatment for novel coronavirus disease. It was observed that viral clearance time was reduced in people who were given Favipiravir and 91% of them had witnessed improved CT scans. Another study conducted in Wuhan illustrated that the drug is effective in shortening the fever duration from an average of 4.2 days to 2.5 days. One more such study was conducted in China wherein 340 COVID-19 infected patients were administered with favipiravir, where they recovered quickly and showed greater lung improvement with no obvious side effects. After such evidence from various studies, China approved the use of favipiravir for the treatment of COVID-19 disease. After this, in March 2021, Italy also started the use of this drug for treating novel coronavirus disease and has started clinical trials also. Additionally, the clinical trials are going on in the U.S., Italy and Japan and as of now it is believed that the drug could come out as a potential treatment for COVID-19. This is expected to positively influence the market growth during forecast period.
Major players operating in the Asia Pacific favipiravir market include Fujifilm Toyoma Chemicals Co. Ltd., Zhejiang Hisun Pharmaceuticals, Cipla Limited, Sun Pharmaceutical Industries Limited, Glenmark Pharmaceuticals Limited, Dr. Reddy's Laboratories Limited, Lupin Limited, Beacon Pharmaceuticals Limited and others. The companies are developing advanced technologies and launching new services in order to stay competitive in the market. Other competitive strategies include mergers & acquisitions and new service developments.
Years considered for this report:
- Historical Years: 2016-2019
- Base Year: 2020
- Estimated Year: 2021
- Forecast Period: 2022-2026
Objective of the Study:
- To analyze and estimate the market size of Asia Pacific favipiravir market from 2016 to 2020.
- To estimate and forecast the market size of Asia Pacific favipiravir market from 2021 to 2026 and growth rate until 2026.
- To classify and forecast Asia Pacific favipiravir market based on type, distribution channel, application, company and regional distribution.
- To identify dominant region or segment in the Asia Pacific favipiravir market.
- To identify drivers and challenges for Asia Pacific favipiravir market.
- To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in Asia Pacific favipiravir market.
- To identify and analyze the profile of leading players operating in Asia Pacific favipiravir market.
- To identify key sustainable strategies adopted by market players in Asia Pacific favipiravir market.
The publisher performed both primary as well as exhaustive secondary research for this study. Initially, the publisher sourced a list of manufacturers across the region. Subsequently, the publisher conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, the publisher could include the manufacturers which could not be identified due to the limitations of secondary research. The publisher analyzed the manufacturers, distribution channels and presence of all major players across the region.
The publisher calculated the market size of Asia Pacific favipiravir market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The publisher sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.
Key Target Audience:
- Favipiravir manufacturers, suppliers, distributors and other stakeholders
- Government bodies such as regulating authorities and policy makers
- Organizations, forums and alliances related to favipiravir
- Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as service providers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.
Report Scope:
In this report, Asia Pacific favipiravir market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Asia Pacific Favipiravir Market, By Type:
- Original Drug
- Generic Drug
Asia Pacific Favipiravir Market, By Distribution Channel:
- Hospitals & Clinics
- Drug Stores/Pharmacies
- Online
Asia Pacific Favipiravir Market, By Application:
- Influenza A&B
- Ebola
- COVID-19
- Others
Asia Pacific Favipiravir Market, By Country:
- China
- India
- Japan
- South Korea
- Australia
- Singapore
- Thailand
- Vietnam
- Malaysia
- Bangladesh
- Pakistan
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in Asia Pacific favipiravir market.
Available Customizations:
With the given market data, the publisher offers customizations according to a company’s specific needs.
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Fujifilm Toyoma Chemicals Co Ltd
- Zhejiang Hisun Pharmaceuticals
- Cipla Limited
- Sun Pharmaceutical Industries Limited
- Glenmark Pharmaceuticals Limited
- Dr Reddy's Laboratories Limited
- Lupin Limited
- Beacon Pharmaceuticals Limited
